Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 1

Status

Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

OTHER 50INDUSTRY 47NIH 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 9Other hematologic neoplasm 4

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cytarabine 117Cyclophosphamide 88Etoposide 59Daunorubicin 58fludarabine phosphate 50Specimen Handling 49Methotrexate 49Filgrastim 48Vincristine 47Biopsy 47Rituximab 43Radiotherapy 34Dexamethasone 34Peripheral Blood Stem Cell Transplantation 32Doxorubicin 29Mitoxantrone 27Idarubicin 27Busulfan 27Azacitidine 27Prednisone 26Mercaptopurine 26Leucovorin 26fludarabine 25Decitabine 24Asparaginase 24venetoclax 23merphos 22Bortezomib 22Cyclosporine 20alvocidib 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
NIH × obinutuzumab × Other hematologic neoplasm × Clear all
NCT03701282 2026-05-29

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
720 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03737981 2026-05-29

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 3 Active not recruiting
465 enrolled 11 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04269902 2026-05-19

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

National Cancer Institute (NCI)

Phase 3 Recruiting
247 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03759184 2022-03-22

Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
1 enrolled 13 charts
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡